frustrate
发表于 2025-3-21 17:25:01
书目名称Lymphohaematopoietic Growth Factors in Cancer Therapy II影响因子(影响力)<br> http://impactfactor.cn/if/?ISSN=BK0589218<br><br> <br><br>书目名称Lymphohaematopoietic Growth Factors in Cancer Therapy II影响因子(影响力)学科排名<br> http://impactfactor.cn/ifr/?ISSN=BK0589218<br><br> <br><br>书目名称Lymphohaematopoietic Growth Factors in Cancer Therapy II网络公开度<br> http://impactfactor.cn/at/?ISSN=BK0589218<br><br> <br><br>书目名称Lymphohaematopoietic Growth Factors in Cancer Therapy II网络公开度学科排名<br> http://impactfactor.cn/atr/?ISSN=BK0589218<br><br> <br><br>书目名称Lymphohaematopoietic Growth Factors in Cancer Therapy II被引频次<br> http://impactfactor.cn/tc/?ISSN=BK0589218<br><br> <br><br>书目名称Lymphohaematopoietic Growth Factors in Cancer Therapy II被引频次学科排名<br> http://impactfactor.cn/tcr/?ISSN=BK0589218<br><br> <br><br>书目名称Lymphohaematopoietic Growth Factors in Cancer Therapy II年度引用<br> http://impactfactor.cn/ii/?ISSN=BK0589218<br><br> <br><br>书目名称Lymphohaematopoietic Growth Factors in Cancer Therapy II年度引用学科排名<br> http://impactfactor.cn/iir/?ISSN=BK0589218<br><br> <br><br>书目名称Lymphohaematopoietic Growth Factors in Cancer Therapy II读者反馈<br> http://impactfactor.cn/5y/?ISSN=BK0589218<br><br> <br><br>书目名称Lymphohaematopoietic Growth Factors in Cancer Therapy II读者反馈学科排名<br> http://impactfactor.cn/5yr/?ISSN=BK0589218<br><br> <br><br>
奖牌
发表于 2025-3-21 20:13:48
http://reply.papertrans.cn/59/5893/589218/589218_2.png
OPINE
发表于 2025-3-22 03:02:47
Analysis of T-Cell Receptor Variability in Tumour Infiltrating Lymphocytesrequired to increase response rates and to improve the quality of tumour regression. The beneficial effects are to a great extent adoptive, as strongly suggested by the study of antitumour responses in immuno-depleted animals; the critical effectors of the antitumour response are the transfused cells.
Abominate
发表于 2025-3-22 08:36:21
Clinical Studies with Interleukin-2: An Overviewmone intimately involved in the induction and sustenance of virtually all of the immune responses of T cells. After the discovery of the genetic sequence in 1983, production of rh-IL-2 on a large-scale basis became possible, allowing extensive clinical testing .
Synchronism
发表于 2025-3-22 11:59:35
http://reply.papertrans.cn/59/5893/589218/589218_5.png
考博
发表于 2025-3-22 15:32:41
http://reply.papertrans.cn/59/5893/589218/589218_6.png
lambaste
发表于 2025-3-22 19:46:38
Clinical Trials with Local Administration of Lymphopoietic Growth Factorsaction mechanisms both . and . . Efforts have, therefore, been made to use ILs to modulate immune responses. This approach has been rendered easier by recombinant DNA technology, which has made several ILs available in unlimited amounts.
Fresco
发表于 2025-3-22 23:22:48
Clinical Trials with Interleukin-2. The Rome Experiencestitute of Rome, partially in collaboration with the Laboratory of Haematology and Oncology of the Italian National Institute of Health and the Department of Haematology of “La Sapienza” University, Rome.
ZEST
发表于 2025-3-23 02:38:36
http://reply.papertrans.cn/59/5893/589218/589218_9.png
BOOST
发表于 2025-3-23 08:43:20
Overview: 978-3-642-77803-2978-3-642-77801-8